Valuation: Lakefront Biotherapeutics NV

Market Cap 1.61B 1.83B 1.5B 1.38B 2.59B 177B 2.63B 17.83B 6.96B 86.88B 6.89B 6.74B 301B P/E 2026 *
-11.5x
P/E 2027 * -8.68x
Enterprise Value -369M -419M -343M -315M -591M -40.47B -600M -4.07B -1.59B -19.85B -1.57B -1.54B -68.69B EV / Sales 2026 *
-25.9x
EV / Sales 2027 * -8.22x
Free-Float
74.64%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Lakefront Biotherapeutics NV

1 day-1.13%
1 week-5.77%
Current month-6.56%
1 month-3.54%
3 months+0.57%
6 months-16.44%
Current year-12.50%
1 week 24.5
Extreme 24.5
26.46
1 month 24.5
Extreme 24.5
27.12
Current year 22.62
Extreme 22.62
30.72
1 year 22.62
Extreme 22.62
32.74
3 years 20
Extreme 20
40.26
5 years 20
Extreme 20
66.28
10 years 20
Extreme 20
252.9
Manager TitleAgeSince
Chief Executive Officer 53 2025-05-11
Director of Finance/CFO 41 2025-07-06
Chief Operating Officer - 2026-05-31
Director TitleAgeSince
Director/Board Member 63 2019-10-21
Director/Board Member 49 2024-10-06
Director/Board Member 53 2025-05-11
Date Insider Type Main position Quantity % Market Cap.
1/28/26 Buy

Chairman

1,559 0.0024%
1/28/26 Buy

Director

375 0.0006%
1/28/26 Free

General Counsel

235,000 0.3566%
Change 5-day change 1-year change 3-year change Capi.($)
-1.13%-5.77%-4.00%-35.80% 1.84B
+1.07%-3.49%-3.25%+12.87% 46.86B
+0.25%+1.65%+408.41%+629.49% 40.23B
-0.27%+4.45%+9.93%+66.92% 36.23B
+0.35%+0.87%+3.60%-8.81% 34.72B
+3.14%+1.02%+3.37%+38.15% 27.89B
-0.73%+11.84%+31.97%+143.53% 16.79B
+0.47%-2.74% - - 16.74B
+0.42%-5.52%+0.76%+8.50% 13.12B
-2.68%-2.49%-15.00%-31.68% 12.7B
Average +0.09%+0.17%+48.42%+91.46% 24.71B
Weighted average by Cap. +0.47%+0.86%+74.68%+135.27%

Financials

2026 *2027 *
Net sales 14.24M 16.18M 13.24M 12.15M 22.81M 1.56B 23.18M 157M 61.39M 766M 60.76M 59.45M 2.65B 46.09M 52.38M 42.85M 39.32M 73.82M 5.06B 75.02M 509M 199M 2.48B 197M 192M 8.58B
Net income -811M -921M -754M -692M -1.3B -88.97B -1.32B -8.96B -3.49B -43.62B -3.46B -3.38B -151B -238M -270M -221M -203M -381M -26.1B -387M -2.63B -1.03B -12.8B -1.01B -993M -44.29B
Net Debt -1.98B -2.25B -1.84B -1.69B -3.18B -218B -3.23B -21.91B -8.55B -107B -8.46B -8.28B -369B -1.99B -2.27B -1.85B -1.7B -3.19B -219B -3.25B -22.02B -8.59B -107B -8.51B -8.32B -371B
Logo Lakefront Biotherapeutics NV
Lakefront Biotherapeutics NV (formerly Galapagos NV) is a biotechnology company built to bring meaningful medicines to patients with serious diseases in therapeutic areas of unmet need. The Company combines world-class deal making expertise with capital to identify, acquire, and advance promising opportunities that have the potential to drive value for patients and shareholders. Applying a modality-agnostic asset selection approach and operational flexibility, Lakefront Biotherapeutics NV prioritizes oncology and immunology & inflammation programs with clear clinical proof-of-concept in emerging areas.
Employees
452
Date Price Change Volume
26-07-24 €24.50 -1.13% 65,584
26-07-23 €24.78 -3.35% 108,761
26-07-22 €25.64 0.00% 49,642
26-07-21 €25.64 -0.23% 62,455
26-07-20 €25.70 -1.15% 72,797
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
9
Last Close Price
24.50EUR
Average target price
30.28EUR
Spread / Average Target
+23.57%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LKFT Stock